<DOC>
	<DOCNO>NCT00582036</DOCNO>
	<brief_summary>To determine whether intensive glucose control result improve mortality reduce hospital stay length perform randomize trial intensive glucose management ( blood glucose goal 110 mg/dl ) use continuous IV insulin glucose vs. non-intensive glucose management ( goal 200 mg/dl )</brief_summary>
	<brief_title>Glucose Control In Hematopoetic Stem Cell Transplant</brief_title>
	<detailed_description>TO determine whether few infection , day without fever , day antibiotic give infection time marrow engraftment improve intensive glucose management ; determine whether evidence reduction measure inflammation patient randomize intensive glucose management whether reduction inflammation associate outcome .</detailed_description>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Patients older 18 Must meet standard criterion HSCT If patient know diabetic admit may maintain home sulfonylurea insulin randomize conventional arm If intensive arm patient must stop oral hyperglycemic med</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Hyperglycemia</keyword>
	<keyword>Hematopoietic stem cell transplantation</keyword>
	<keyword>Bone marrow transplant</keyword>
	<keyword>High blood sugar</keyword>
</DOC>